I just read in a science magazine that a company was working on a drug that does not treat the symptom but actually treats the disease itself, It is currently being trialed and tested now. The drug is called PD01A and the company is Affiris in Vienna Austria.
How low will this go? Should I buy more or wait. Is this the bottom or what? It still has an analyst target of 20 buck?
Can anyone shed some light on this. I am not worried about the risk of the approval as much as the litigation. Wont this take away cash from the company to fight the legal BS. I also emailed the company and asked them to comment on this but don't think we will here much.
Pomerantz Law Firm Has Filed a Class Action Against Chelsea Therapeutics International Ltd. -- CHTP
How will this affect investors. Not good I think!